Pipeline
Ifebemtinib / IN10018 Clinical Study
| Proof of Concept | Registration | ||||
|---|---|---|---|---|---|
|
+ Chemo + αPD-(L)1 Frontline ES-SCLC NCT06030258 RCT |
+ MEKi ± αPD-(L)1 Met UM & NRAS Melanoma NCT04109456 |
+ PLD + αPD-(L)1 2L+ TNBC NCT05830539 |
+ KRAS G12Ci 1L NSCLC & 2L+ CRC NCT06166836 RCT |
+ 3G EGFR TKI Frontline NSCLC NCT05994131 RCT |
+ PLD PROC NCT06014528 |
Additional Pipeline Assets
| First in Human | Preclinical | ||
|---|---|---|---|
|
OMTX705 FAP ADC Solid Tumor NCT05547321 |
IN30718 ADC, target undisclosed Solid Tumor |
IN30728 ADC, target undisclosed Solid Tumor |
IN30738 ADC, target undisclosed Solid Tumor |
|
▬ Ongoing ▬ Achieved RCT Randomized Control Trial Chemo: chemotherapy ES-SCLC: extensive-stage small cell lung cancer PLD: pegylated liposomal doxorubicin PROC: platinum-resistant recurrent ovarian cancer |
UM: uveal melanoma TNBC: triple-negative breast cancer NSCLC: non-small cell line cancer CRC: colorectal cancer EGFR TKI: epidermal growth factor receptor tyrosine kinase inhibitor ADC: antibody-drug conjugate FAP: fibroblast activation protein-α |
Ifebemtinib
Ifebemtinib (also known as IN10018, ifebe, BI853520) is an orally administered, highly potent and selective small molecular inhibitor of the focal adhesion kinase (FAK). InxMed translational research has demonstrated the essential functions of FAK in tumor defense.
OMTX705
OMTX705 is an ADC formed by a new humanized anti-FAP mAb that has been conjugated to a novel cytolysin, TAM470, a synthetic microtubule inhibitor from the tubulysin family. IN30705 is designed to target FAP-expressing Cancer Associated Fibroblasts (CAFs) in tumor microenvironment.
NEXT GENERATION ADC
InxMed has developed ADC to address with aims of stronger, more potent ADC to overcome emerging resistance and companion biomarker test sparing.
We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE
Follow Us：
CopyRight © 2022 InxMed All Rights Reserved.